{"gene":"CCL2","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1999,"finding":"MCP-1 (CCL2) rapidly triggers firm adhesion of rolling monocytes to vascular endothelium under flow conditions by acting on endothelium expressing E-selectin; this effect is independent of calcium transient induction or chemotaxis, revealing a distinct adhesion-promoting mechanism separate from classical chemotaxis.","method":"Flow chamber adhesion assay with endothelial monolayers transduced to express specific leukocyte-adherence receptors; calcium imaging","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1/2 / Strong — direct functional assay under physiological flow conditions with orthogonal measurements (adhesion, calcium, chemotaxis) dissecting mechanism; published in high-impact venue","pmids":["10227295"],"is_preprint":false},{"year":2003,"finding":"CCL2/MCP-1 protects mixed cultures of human neurons and astrocytes from NMDA- or HIV-Tat-induced apoptosis by reducing extracellular glutamate levels and NMDA receptor 1 (NMDAR1) expression, and by decreasing intracellular Tat; the protective effect of RANTES was blocked by anti-MCP-1 antibody, indicating RANTES acts via induction of MCP-1.","method":"Cell culture apoptosis assay, extracellular glutamate measurement, NMDAR1 Western blot, anti-MCP-1 neutralizing antibody blockade, NMDA receptor blocker MK801","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in one study, single lab, in vitro model","pmids":["12753088"],"is_preprint":false},{"year":2003,"finding":"PKCβ isoform is specifically required for MCP-1-induced chemotaxis of human monocytes; antisense knockdown of PKCβ caused ~89% inhibition of chemotaxis without affecting the MCP-1/CCR2-triggered calcium signal, placing PKCβ downstream of the initial receptor-calcium response in the chemotactic signaling cascade.","method":"Antisense oligodeoxyribonucleotide knockdown of specific PKC isoforms; PKC pharmacological inhibitors (GF109203X, Calphostin C); chemotaxis assay; calcium response measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — isoform-specific antisense knockdown combined with pharmacological inhibition and calcium signaling dissection in one study","pmids":["12724308"],"is_preprint":false},{"year":2004,"finding":"TGF-β1 inhibition of MCP-1 expression in macrophages is mediated specifically by Smad3; Smad3 overexpression potently repressed inducible MCP-1 expression, and TGF-β1 inhibition of cytokine-induced MCP-1 was completely lost in Smad3-deficient macrophages. Mechanistically, Smad3 antagonizes AP-1 (c-Jun/c-Fos) DNA binding and activity at the MCP-1 promoter.","method":"Adenoviral Smad3 overexpression; Smad3-knockout macrophages; AP-1 DNA-protein binding assay; cardiac allograft model with accelerated arteriopathy in Smad3-KO mice","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic knockout plus gain-of-function with mechanistic AP-1 binding assay in one study, in vitro and in vivo validation","pmids":["14752027"],"is_preprint":false},{"year":2005,"finding":"CCL2/MCP-1 protects cardiac myocytes from hypoxia-induced apoptosis through ERK1/2 signaling (not through Gαi, which mediates monocyte chemotaxis); CCL2 treatment decreased caspase-3 activation and JNK/SAPK phosphorylation, increased Bcl-xL and Bag-1, and decreased Bax, demonstrating cytoprotection and chemotaxis use distinct signaling pathways.","method":"Cardiac myocyte hypoxia apoptosis assay; ERK1/2 pathway inhibitor; Gαi inhibitor (pertussis toxin); Western blot for Bcl-2 family proteins, caspase-3, JNK/SAPK","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple signaling pathway dissections in one study, single lab, in vitro model","pmids":["16102724"],"is_preprint":false},{"year":2008,"finding":"MCP-1 (CCL2) upregulation in P0-mutant (myelin-deficient) Schwann cells is mediated by the MEK1/2–ERK1/2 signaling pathway; MEK1/2 inhibitor CI-1040 reduced ERK1/2 phosphorylation and MCP-1 expression in Schwann cell lines in vitro and in peripheral nerves of P0+/− mice in vivo.","method":"Western blot of peripheral nerve lysates for phospho-ERK1/2 and phospho-MEK1/2; MEK1/2 inhibitor CI-1040 in vitro and systemic in vivo treatment; MCP-1 ELISA","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway inhibition with in vitro and in vivo validation, single lab","pmids":["18383340"],"is_preprint":false},{"year":2008,"finding":"12(S)-HETE (a 12/15-lipoxygenase product) increases MCP-1 mRNA and protein expression in macrophages via PKC, p38 MAPK, and NADPH oxidase activity; genetic knockout of 12/15-LO reduced macrophage MCP-1 expression, while overexpression increased it.","method":"12/15-LO knockout and transgenic mice; stable 12/15-LO overexpressing macrophage cell line; pharmacological inhibitors of PKC, p38, and NADPH oxidase; MCP-1 ELISA and RT-PCR","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic gain/loss-of-function plus pharmacological dissection of three parallel signaling nodes, replicated across multiple models","pmids":["18296557"],"is_preprint":false},{"year":2009,"finding":"Noradrenaline induces MCP-1 expression in astrocytes via β2-adrenergic receptor and cAMP signaling, and this astrocyte-derived MCP-1 reduces NMDA-dependent glutamate release and Ca2+ entry in neurons, thereby mediating neuroprotection; neutralizing antibody to MCP-1 blocked conditioned medium-mediated protection, and MCP-1 dose-dependently reduced neuronal damage from NMDA, glutamate, and oxygen-glucose deprivation.","method":"Primary astrocyte and neuron cultures; MCP-1 promoter-luciferase reporter; β2-adrenergic receptor antagonist; cAMP analog; neutralizing anti-MCP-1 antibody; intracellular Ca2+ measurement; LDH release assay; ATP measurement; oxygen-glucose deprivation model","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — promoter reporter, receptor pharmacology, antibody neutralization, and multiple functional readouts in one study","pmids":["19129402"],"is_preprint":false},{"year":2009,"finding":"MCP-1 expressed by osteoclasts stimulates osteoclastogenesis in an autocrine/paracrine manner under RANKL stimulation; MCP-1-deficient osteoclast precursors showed impaired multinuclear osteoclast formation, downregulation of DC-STAMP, NFATc1, and cathepsin K, and these defects were rescued by recombinant MCP-1 but not by rescuing DC-STAMP, indicating MCP-1 acts upstream of DC-STAMP in the osteoclastogenesis pathway.","method":"MCP-1 knockout mouse osteoclast cultures; recombinant MCP-1 rescue; DC-STAMP-deficient mouse cells; RT-PCR for osteoclast differentiation markers","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus recombinant protein rescue with epistasis experiment, single lab","pmids":["19364494"],"is_preprint":false},{"year":2010,"finding":"MCP-1 promotes mural cell recruitment during angiogenesis; angiopoietin-1-induced mural cell recruitment requires MCP-1 (anti-MCP-1 antibody blocks Ang-1 effect), and aortic rings from MCP-1-knockout or CCR2-knockout mice have fewer mural cells; recombinant MCP-1 dose-dependently increases mural cell number.","method":"Aortic ring angiogenesis model; MCP-1 and CCR2 knockout mice; anti-MCP-1 blocking antibody; recombinant MCP-1 addition; p38 MAPK inhibitor","journal":"Angiogenesis","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO (two genes), antibody neutralization, and recombinant protein gain-of-function all converge on same conclusion","pmids":["20571857"],"is_preprint":false},{"year":2013,"finding":"MCP-1 binds to oxidized LDL (OxLDL) via basic amino acid residues Arg-18 and Lys-19; mutation of these residues abolished OxLDL binding. OxLDL-bound MCP-1 retains monocyte-recruiting activity. MCP-1 also binds Lp(a) in human plasma through oxidized phospholipids (OxPLs), as demonstrated by E06 monoclonal antibody (anti-OxPL) inhibition.","method":"Site-directed mutagenesis (Arg18Ala/Lys19Ala); OxLDL binding assay; E06 monoclonal antibody inhibition; recombinant MCP-1 spiking into human plasma; Lp(a) capture and MCP-1 ELISA; monocyte migration assay","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis identifying binding residues combined with antibody blockade and in vivo plasma binding experiments","pmids":["23667177"],"is_preprint":false},{"year":2013,"finding":"IκBζ, an atypical IκB family member, is a key transcriptional activator of the Ccl2 (MCP-1) gene; IκBζ-deficient macrophages show impaired CCL2 secretion in response to LPS or peptidoglycan, IκBζ is directly recruited to the proximal Ccl2 promoter (by ChIP), and promotes transcription-enhancing H3K4me3 histone marks. In vivo, IκBζ-KO mice show impaired CCL2 secretion and monocyte infiltration in peritonitis.","method":"IκBζ-knockout macrophages; ELISA for CCL2; chromatin immunoprecipitation (ChIP) for IκBζ occupancy and H3K4me3; in vivo peritonitis model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic KO, ChIP demonstrating direct promoter binding, histone mark analysis, and in vivo validation in one study","pmids":["23547114"],"is_preprint":false},{"year":2014,"finding":"ATF3 binds ATF/CRE sites in the MCP-1 promoter and transcriptionally represses MCP-1 expression in renal epithelial cells after ischemia/reperfusion (I/R) injury; ATF3-knockout mice showed higher MCP-1 induction after I/R. Exosomal ATF3 RNA from epithelial cells also inhibited MCP-1 expression and macrophage migration.","method":"ATF3 knockout mice; I/R injury model; chromatin immunoprecipitation/promoter binding assay for ATF3 at MCP-1 promoter; exosome isolation and transfer; MCP-1 ELISA; macrophage migration assay","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and direct promoter binding shown, single lab with in vitro and in vivo components","pmids":["24420912"],"is_preprint":false},{"year":2014,"finding":"MCP-1 promotes invasion and adhesion of human ovarian cancer (SKOV-3) cells via CCR2; CCR2 antagonist blocked MCP-1-induced invasion and adhesion, and CCR2 expression was confirmed in SKOV-3 cells.","method":"Transwell invasion assay; cell adhesion assay; CCR2 antagonist treatment; immunohistochemistry for CCR2","journal":"Anticancer research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, receptor antagonist only, in vitro model","pmids":["24222114"],"is_preprint":false},{"year":2014,"finding":"MCP-1 stimulates spinal microglia via the PI3K/Akt pathway in bone cancer pain; intrathecal anti-MCP-1 antibody or PI3K inhibitor LY294002 reduced p-Akt and OX-42 expression in spinal dorsal horns, and LY294002 attenuated mechanical allodynia.","method":"Bone cancer pain rat model; in vitro microglia stimulation with recombinant MCP-1; Western blot for p-Akt and OX-42; pharmacological PI3K inhibitor; intrathecal anti-MCP-1 neutralizing antibody; behavioral pain testing","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo pharmacological dissection with behavioral readout, single lab","pmids":["25555372"],"is_preprint":false},{"year":2018,"finding":"MCP-1 drives triple-negative breast cancer cell invasion via the CCR2 receptor and MAP kinase (MEK/ERK) pathway; CCR2 antagonist and MEK inhibitor U0126 both blocked MCP-1-induced invasion; MCP-1 knockdown in BT-549 cells decreased invasion and downregulated EMT markers N-cadherin and vimentin.","method":"Boyden chamber invasion assay; CCR2 antagonist; MEK inhibitor U0126; siRNA knockdown of MCP-1; qRT-PCR and ELISA for MCP-1; Western blot for EMT markers","journal":"Breast cancer research and treatment","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic (siRNA) approaches with multiple downstream readouts, single lab","pmids":["29594759"],"is_preprint":false},{"year":2018,"finding":"MCP-1/CCR2 signaling mediates ethanol-induced microglial activation/neuroinflammation and neuroapoptosis in the developing brain; MCP-1-KO and CCR2-KO mice were more resistant to ethanol-induced neuroapoptosis; MCP-1 inhibitor (Bindarit) and CCR2 antagonist (RS504393) reduced neuroinflammation; mechanistically, blocking MCP-1/CCR2 attenuated ethanol-induced activation of TLR4 and GSK3β.","method":"MCP-1-KO and CCR2-KO mice; ethanol neonatal exposure model; immunohistochemistry and immunoblotting; neuron/microglia co-culture; pharmacological inhibitors Bindarit and RS504393; TLR4 and GSK3β signaling analysis","journal":"Journal of neuroinflammation","confidence":"High","confidence_rationale":"Tier 2 / Strong — dual genetic knockout models, pharmacological inhibition, in vitro co-culture, and mechanistic signaling pathway dissection, replicated across models","pmids":["29976212"],"is_preprint":false},{"year":2019,"finding":"I/R-induced MCP-1 release regulates cardiomyocyte apoptosis via CaSR (Ca2+-sensing receptor) acting as upstream effector of MCPIP1 (MCP-1-induced protein 1), which in turn activates ER stress but not autophagy; CCR2 inhibitor RS-102895 and CaSR inhibitor NPS-2143 both reduced I/R-induced apoptosis.","method":"HL-1 cardiac cells and primary neonatal cardiomyocytes; simulated I/R; CCR2 inhibitor (RS-102895); CaSR inhibitor (NPS-2143) and activator (evocalcet); Hoechst staining and flow cytometry apoptosis; ER stress markers by Western blot; ELISA for MCP-1","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection of CaSR-MCPIP1-ER stress axis with multiple inhibitor/activator tools, single lab, in vitro","pmids":["31774703"],"is_preprint":false},{"year":2023,"finding":"In NASH, hepatocyte-specific Notch signaling transactivates the Ccl2 promoter via an evolutionarily conserved Notch/RBPJ binding site, driving hepatocyte-derived MCP-1 secretion that recruits monocyte-derived macrophages and causes liver fibrosis; hepatocyte-specific Ccl2-KO reduced MoMF infiltrate and fibrosis, while forced hepatocyte MCP-1 expression caused the opposite phenotype, and CCR2 inhibitor ameliorated these effects.","method":"Hepatocyte-specific Ccl2-KO mice; hepatocyte-specific Notch gain-of-function mice; CCR2 inhibitor treatment; Ccl2 promoter analysis (RBPJ site); NASH diet mouse model; liver histology for fibrosis and macrophage markers","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — hepatocyte-specific KO and OE genetic models, promoter mechanism identified (Notch/RBPJ site), pharmacological CCR2 inhibition, in vivo fibrosis readout","pmids":["36752206"],"is_preprint":false},{"year":1996,"finding":"Lysophosphatidylcholine (LPC) stimulates MCP-1 mRNA expression and protein secretion in human vascular endothelial cells (HUVECs) via protein kinase C (PKC) pathway; PKC inhibitor staurosporine attenuated LPC-induced MCP-1 mRNA increase by 53%.","method":"HUVEC cultures; LPC treatment; ELISA for MCP-1 protein; Northern blot/mRNA quantification; staurosporine (PKC inhibitor) co-treatment","journal":"Metabolism: clinical and experimental","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single pharmacological inhibitor approach, single lab, partial mechanistic follow-up","pmids":["8622597"],"is_preprint":false},{"year":2003,"finding":"Smad-3 stimulates basal and HIV-1 Tat-mediated MCP-1 transcription in human astrocytic cells, while Smad-4 decreases both Smad-3- and Tat-induced MCP-1 promoter activity; Smad-3 and Smad-4 physically associate with the N-terminal region (residues 1–40) of Tat, and the MH2 domain of Smad-3 is required for this transcriptional cooperation.","method":"Transfection reporter assays (MCP-1 promoter-luciferase); protein-binding studies (co-association of Smad domains with Tat); domain deletion/mutation analysis of Smad","journal":"Virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional promoter reporter assays plus protein-protein interaction mapping with domain deletions, single lab","pmids":["12758167"],"is_preprint":false},{"year":2010,"finding":"p53 directly binds to a site ~2.5 kb upstream of the MCP-1 transcriptional start site (confirmed by EMSA and ChIP) and is required for TNF-α-induced MCP-1 transcription in keratinocytes; HPV E6-mediated p53 degradation abolishes TNF-α-induced MCP-1 expression, and siRNA against p53 decreased MCP-1 transcription, confirming a p53–MCP-1 transcriptional axis.","method":"EMSA (electrophoretic mobility shift assay); chromatin immunoprecipitation (ChIP); siRNA knockdown of p53; HPV E6/E7 expressing cell lines; temperature-sensitive p53 mutant cells; Li-Fraumeni cells","journal":"Molecular cancer","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct p53 binding shown by both EMSA and ChIP, functional siRNA knockdown, multiple genetic cell systems all converging","pmids":["20406462"],"is_preprint":false},{"year":2003,"finding":"17β-estradiol (E2) inhibits MCP-1 gene expression in keratinocytes through estrogen receptor beta (ERβ), which physically associates (co-immunoprecipitation) with Sp1 or AP-1 in an E2-dependent manner, inhibiting their transcriptional activity at the Sp1 and AP-1 elements in the MCP-1 promoter without blocking their DNA binding.","method":"MCP-1 promoter-luciferase reporter; ERβ transfection; estrogen receptor antagonist ICI 182780; Sp1 and AP-1 transcriptional activity assays; co-immunoprecipitation (ERβ with Sp1/AP-1); ERβ domain deletion/mutation analysis","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — promoter reporter assay, co-IP for protein interaction, receptor domain mutagenesis, and multiple transcription factor dissections in one study","pmids":["12787135"],"is_preprint":false},{"year":2014,"finding":"Dominant negative MCP-1 (7ND) blocks human osteoclast differentiation by preventing early induction of calmodulin 1 (CALM1), JUN, and NFATc2; MCP-1 mRNA was induced >1000-fold within 24 h of RANKL treatment, preceding induction of NFATc1, NFATc2, cathepsin K, and TRAP, placing MCP-1 induction at the apex of the RANKL-driven osteoclastogenesis cascade.","method":"Human cord blood CFU-GM differentiation to osteoclasts; quantitative PCR for multiple osteoclast markers over time course; dominant negative MCP-1 (7ND) treatment; temporal gene expression profiling","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant negative inhibition with comprehensive temporal gene expression profiling establishing pathway ordering, single lab","pmids":["23996571"],"is_preprint":false},{"year":2021,"finding":"Adiponectin suppresses TNF-α-stimulated MCP-1 expression in hepatocytes via the APPL2-mTORC1 signaling axis; hepatocyte-specific APPL2 knockout enhanced adiponectin sensitivity, blocked TNF-α-induced MCP-1 expression, and reduced macrophage infiltration and hepatic inflammation, while concomitant adiponectin knockout reversed these effects.","method":"Hepatocyte-specific APPL2 KO mice; adiponectin KO mice; double KO strategy; high-fat diet model; mTORC1 signaling analysis; macrophage infiltration histology; MCP-1 ELISA","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — dual genetic KO epistasis (APPL2 and adiponectin) with pathway (mTORC1) identification and in vivo macrophage infiltration readout","pmids":["34162682"],"is_preprint":false},{"year":2006,"finding":"High-glucose/hyperosmolarity-induced MCP-1 expression in peritoneal mesothelial cells is mediated by PKC activation and downstream NF-κB (not by MEK/ERK, p38 MAPK, or JNK); prednisolone inhibited NF-κB DNA binding and MCP-1 expression by increasing IκBα, and this effect was reversed by a glucocorticoid receptor antagonist.","method":"Rat peritoneal mesothelial cells; high-glucose/mannitol treatment; pharmacological inhibitors of PKC, NF-κB, MEK, p38, JNK; EMSA for NF-κB binding; Western blot; MCP-1 RT-PCR and ELISA; glucocorticoid receptor antagonist mifepristone","journal":"Kidney international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic pharmacological dissection of multiple signaling pathways with EMSA confirmation, single lab","pmids":["16518329"],"is_preprint":false}],"current_model":"CCL2/MCP-1 is a CC chemokine secreted by diverse cell types that functions primarily through its G-protein-coupled receptor CCR2 to recruit monocytes and macrophages to sites of inflammation; its chemotactic signaling requires PKCβ downstream of the receptor-calcium signal, while separate ERK1/2-dependent pathways mediate cytoprotection in neurons and cardiomyocytes; MCP-1 transcription is regulated by multiple mechanisms including NF-κB/IκBζ co-activation, direct p53 binding to the promoter, Smad3-mediated AP-1 antagonism downstream of TGF-β, Notch/RBPJ transactivation in hepatocytes, ERβ–Sp1/AP-1 inhibition by estradiol, and MEK-ERK-dependent upregulation in Schwann cells; MCP-1 also binds oxidized LDL and Lp(a) via Arg-18/Lys-19 residues and retains monocyte-recruiting activity in this lipid-bound form, acts autocrine/paracrine to support osteoclastogenesis upstream of DC-STAMP and NFATc1, and mediates mural cell recruitment during angiogenesis downstream of angiopoietin-1/p38 MAPK."},"narrative":{"mechanistic_narrative":"CCL2/MCP-1 is a secreted CC chemokine that orchestrates myeloid cell recruitment in inflammation, acting primarily through its receptor CCR2 to drive monocyte/macrophage chemotaxis, adhesion, and tissue infiltration [PMID:10227295, PMID:36752206]. Under vascular flow it triggers firm adhesion of rolling monocytes to E-selectin-bearing endothelium, a function dissociable from calcium signaling and chemotaxis [PMID:10227295]; in the chemotactic arm, CCR2 engagement signals through a calcium transient and a downstream PKCβ requirement that is genetically separable from the receptor-calcium step itself [PMID:12724308]. CCL2 also binds oxidized LDL and Lp(a) via its basic residues Arg-18/Lys-19 while retaining monocyte-recruiting activity, linking the chemokine to lipoprotein-associated inflammation [PMID:23667177]. Beyond leukocyte trafficking, CCL2/CCR2 supports osteoclastogenesis, acting upstream of DC-STAMP, NFATc1, calmodulin 1, JUN and NFATc2 at the apex of RANKL-driven differentiation [PMID:19364494, PMID:23996571], and mediates angiopoietin-1-dependent mural cell recruitment during angiogenesis [PMID:20571857]. In parenchymal cells the chemokine engages a distinct, Gαi-independent ERK1/2 program that is cytoprotective in cardiomyocytes and neurons, lowering glutamate/NMDAR1-dependent excitotoxicity and apoptosis [PMID:16102724, PMID:19129402, PMID:12753088]. CCL2 transcription is a highly regulated convergence point: it is positively driven by the atypical IκB family member IκBζ recruited to the proximal Ccl2 promoter with H3K4me3 deposition [PMID:23547114], by direct p53 binding required for TNF-α induction [PMID:20406462], and by Notch/RBPJ transactivation in hepatocytes that fuels macrophage recruitment and fibrosis in NASH [PMID:36752206]; it is repressed by TGF-β1/Smad3 antagonism of AP-1 [PMID:14752027], by ATF3 binding ATF/CRE sites [PMID:24420912], and by estradiol-activated ERβ that sequesters Sp1/AP-1 activity [PMID:12787135]. CCL2 contributes to inflammatory and pathological signaling in cancer invasion, neuroinflammatory pain, ethanol-induced developmental neuroapoptosis, and ischemia/reperfusion injury, generally through CCR2 and MAPK or PI3K/Akt effectors [PMID:29976212, PMID:29594759, PMID:25555372, PMID:31774703].","teleology":[{"year":1999,"claim":"Established that CCL2 has an adhesion-promoting function on endothelium that is mechanistically distinct from its classical chemotactic role, expanding its action beyond chemotaxis.","evidence":"Flow chamber adhesion assay with receptor-transduced endothelial monolayers plus calcium imaging and chemotaxis controls","pmids":["10227295"],"confidence":"High","gaps":["Receptor/signaling pathway mediating the adhesion effect not defined","Did not resolve which endothelial or monocyte molecules execute firm adhesion"]},{"year":2003,"claim":"Resolved the chemotactic signaling cascade by placing PKCβ downstream of the CCR2-triggered calcium response, separating the receptor-proximal calcium signal from the effector step needed for migration.","evidence":"Isoform-specific antisense knockdown plus PKC inhibitors and calcium measurement in human monocytes","pmids":["12724308"],"confidence":"High","gaps":["Substrates of PKCβ in monocyte migration not identified","Link between calcium signal and PKCβ activation not mapped"]},{"year":2003,"claim":"Demonstrated CCL2 cytoprotection in CNS cells by lowering glutamate and NMDAR1 and identified RANTES neuroprotection as acting via MCP-1 induction, showing the chemokine has neuroprotective roles independent of leukocyte recruitment.","evidence":"Neuron/astrocyte apoptosis assays, glutamate measurement, NMDAR1 Western blot, anti-MCP-1 neutralization","pmids":["12753088"],"confidence":"Medium","gaps":["Receptor and intracellular pathway for neuroprotection not defined in this study","In vitro mixed culture only"]},{"year":2003,"claim":"Identified opposing Smad control of CCL2 transcription: Smad-3 cooperates with HIV-1 Tat to stimulate the promoter while Smad-4 represses, mapping direct Smad-Tat interactions, advancing understanding of TGF-β/viral transcriptional input.","evidence":"MCP-1 promoter-luciferase reporters and Smad-Tat protein interaction/domain mapping in astrocytic cells","pmids":["12758167"],"confidence":"Medium","gaps":["Endogenous promoter occupancy not shown","Context-dependence relative to Smad3 repression in macrophages unresolved"]},{"year":2003,"claim":"Defined an estrogen-dependent repression mechanism in which ERβ sequesters Sp1/AP-1 transcriptional activity at the CCL2 promoter without displacing their DNA binding, explaining hormonal suppression of the chemokine.","evidence":"Promoter-luciferase reporters, ERβ domain mutants, and co-IP of ERβ with Sp1/AP-1 in keratinocytes","pmids":["12787135"],"confidence":"High","gaps":["In vivo relevance of ERβ-CCL2 axis not tested","Quantitative contribution of Sp1 vs AP-1 not separated"]},{"year":2004,"claim":"Pinpointed Smad3 as the obligate mediator of TGF-β1 repression of CCL2 in macrophages through antagonism of AP-1 DNA binding, with in vivo arteriopathy consequences, defining a key negative transcriptional brake.","evidence":"Smad3 gain-of-function, Smad3-KO macrophages, AP-1 binding assay, and cardiac allograft model","pmids":["14752027"],"confidence":"High","gaps":["Mechanism of Smad3-AP-1 antagonism (sequestration vs competition) not fully resolved","Promoter elements bound not mapped"]},{"year":2005,"claim":"Showed cytoprotective and chemotactic CCL2 functions use distinct receptor-coupled pathways, with ERK1/2 (not Gαi) mediating anti-apoptotic protection of cardiomyocytes, formally bifurcating CCL2 signaling outputs.","evidence":"Cardiomyocyte hypoxia apoptosis assays with ERK and Gαi (pertussis toxin) inhibitors and Bcl-2 family Western blots","pmids":["16102724"],"confidence":"Medium","gaps":["Receptor coupling ERK in cardiomyocytes not identified","In vitro hypoxia model only"]},{"year":2006,"claim":"Mapped a PKC→NF-κB pathway driving high-glucose/hyperosmolarity induction of CCL2 in mesothelial cells, distinguishing it from MAPK routes and showing glucocorticoid suppression via IκBα.","evidence":"Systematic pharmacological pathway dissection, NF-κB EMSA, and MCP-1 RT-PCR/ELISA in rat mesothelial cells","pmids":["16518329"],"confidence":"Medium","gaps":["Direct promoter occupancy by NF-κB not shown","Single-cell-type in vitro context"]},{"year":2008,"claim":"Extended the inducer repertoire by showing lipoxygenase product 12(S)-HETE and the myelin-deficient Schwann cell state drive CCL2 through PKC/p38/NADPH oxidase and MEK-ERK respectively, linking lipid and neural-injury signals to chemokine output.","evidence":"12/15-LO KO/transgenic mice and macrophage lines; MEK inhibitor CI-1040 in Schwann cells and P0+/- nerves","pmids":["18296557","18383340"],"confidence":"Medium","gaps":["Transcription factor endpoints downstream of these kinases not identified","Whether pathways converge on shared promoter elements unknown"]},{"year":2009,"claim":"Established CCL2 as an apical, autocrine driver of RANKL-induced osteoclastogenesis acting upstream of DC-STAMP, NFATc1, and cathepsin K, defining a non-immune developmental role for the chemokine.","evidence":"MCP-1-KO osteoclast cultures with recombinant rescue and DC-STAMP-KO epistasis; RT-PCR of differentiation markers","pmids":["19364494"],"confidence":"Medium","gaps":["Receptor on osteoclast precursors not confirmed","Single-lab in vitro epistasis"]},{"year":2009,"claim":"Connected adrenergic input to CCL2 neuroprotection, showing β2-AR/cAMP induces astrocytic CCL2 that lowers NMDA-dependent glutamate release and calcium entry to protect neurons across multiple injury paradigms.","evidence":"Primary co-cultures, MCP-1 promoter reporter, β2-AR antagonist, anti-MCP-1 neutralization, calcium/LDH/OGD readouts","pmids":["19129402"],"confidence":"High","gaps":["Neuronal receptor transducing the protective signal not identified","In vivo neuroprotection not tested"]},{"year":2010,"claim":"Demonstrated CCL2/CCR2 is required for angiopoietin-1-driven mural cell recruitment during angiogenesis, broadening its role to vascular wall assembly.","evidence":"Aortic ring model with MCP-1-KO and CCR2-KO mice, anti-MCP-1 blockade, recombinant MCP-1, and p38 inhibitor","pmids":["20571857"],"confidence":"High","gaps":["Mural cell receptor/signaling response not fully defined","Relationship to monocyte recruitment in the same model not separated"]},{"year":2010,"claim":"Identified p53 as a direct transcriptional activator binding a defined upstream site required for TNF-α-induced CCL2, with HPV E6-mediated p53 loss abolishing induction, adding tumor-suppressor control of the chemokine.","evidence":"EMSA and ChIP for p53 binding, siRNA knockdown, and multiple genetic keratinocyte/Li-Fraumeni systems","pmids":["20406462"],"confidence":"High","gaps":["Cofactors enabling p53 at the CCL2 promoter not defined","Generality beyond keratinocytes not established"]},{"year":2013,"claim":"Defined IκBζ as a direct positive regulator recruited to the proximal Ccl2 promoter that deposits activating H3K4me3 and is needed for LPS/peptidoglycan-induced secretion and monocyte infiltration in vivo.","evidence":"IκBζ-KO macrophages, ChIP for occupancy and H3K4me3, and in vivo peritonitis","pmids":["23547114"],"confidence":"High","gaps":["How IκBζ cooperates with NF-κB at the promoter not detailed","Histone methyltransferase recruited not identified"]},{"year":2013,"claim":"Mapped the lipoprotein-binding determinants of CCL2 to Arg-18/Lys-19 and showed the OxLDL/Lp(a)-bound chemokine retains monocyte-recruiting activity, mechanistically linking CCL2 to oxidized lipid carriers in plasma.","evidence":"Site-directed mutagenesis, OxLDL binding assays, E06 anti-OxPL blockade, plasma Lp(a) capture, and migration assays","pmids":["23667177"],"confidence":"High","gaps":["Physiological consequence of lipoprotein-bound delivery in vivo not established","Effect on CCR2 affinity not quantified"]},{"year":2014,"claim":"Added ATF3 as a direct repressor binding ATF/CRE sites in the MCP-1 promoter and revealed exosomal ATF3 RNA as a trans-acting brake limiting macrophage recruitment after renal ischemia/reperfusion.","evidence":"ATF3-KO mice, I/R model, promoter binding assay, exosome transfer, and macrophage migration assay","pmids":["24420912"],"confidence":"Medium","gaps":["Direct binding evidence relies on single-lab assays","Mechanism of exosomal ATF3 RNA action not detailed"]},{"year":2014,"claim":"Placed CCL2 induction at the apex of the RANKL osteoclastogenesis transcriptional cascade, with >1000-fold early induction preceding CALM1/JUN/NFATc2, refining pathway ordering established by earlier KO work.","evidence":"Human CFU-GM osteoclast differentiation with dominant-negative 7ND and temporal qPCR profiling","pmids":["23996571"],"confidence":"Medium","gaps":["Receptor/signal driving the early transcriptional targets not defined","Single-lab temporal profiling"]},{"year":2014,"claim":"Extended CCL2/CCR2 signaling to neuroinflammatory pain via a PI3K/Akt-dependent spinal microglial activation mechanism with behavioral readout.","evidence":"Bone cancer pain rat model, microglia stimulation, PI3K inhibitor LY294002, intrathecal anti-MCP-1, and allodynia testing","pmids":["25555372"],"confidence":"Medium","gaps":["Receptor identity on microglia not confirmed by genetics","Single-lab model"]},{"year":2014,"claim":"Implicated MCP-1/CCR2 in ovarian cancer cell invasion and adhesion, suggesting tumor-cell-intrinsic chemokine signaling, though support rests on antagonist pharmacology alone.","evidence":"Transwell invasion/adhesion assays with CCR2 antagonist and CCR2 immunohistochemistry in SKOV-3 cells","pmids":["24222114"],"confidence":"Low","gaps":["Receptor antagonist only; no genetic confirmation","Single in vitro cell line"]},{"year":2018,"claim":"Defined a CCL2/CCR2→MEK/ERK axis driving triple-negative breast cancer invasion and EMT marker expression, linking autocrine chemokine signaling to tumor cell motility.","evidence":"Invasion assays with CCR2 antagonist, MEK inhibitor U0126, MCP-1 siRNA, and EMT marker Western blots","pmids":["29594759"],"confidence":"Medium","gaps":["In vivo metastatic relevance not tested","Single-lab cell-line study"]},{"year":2018,"claim":"Established a pathogenic CCL2/CCR2 role in ethanol-induced developmental neuroapoptosis acting via TLR4 and GSK3β, using dual genetic and pharmacological tools.","evidence":"MCP-1-KO and CCR2-KO mice, neonatal ethanol model, Bindarit/RS504393 inhibitors, co-culture, and signaling analysis","pmids":["29976212"],"confidence":"High","gaps":["Cell-type source vs target of CCL2 not fully separated","Direct link from CCR2 to TLR4 activation not mechanistically resolved"]},{"year":2019,"claim":"Resolved an intracellular consequence of CCL2/CCR2 in cardiomyocyte I/R injury, placing CaSR upstream of MCPIP1 to activate ER stress (not autophagy) and drive apoptosis.","evidence":"HL-1/primary cardiomyocyte simulated I/R with CCR2 and CaSR inhibitors/activators and ER stress Western blots","pmids":["31774703"],"confidence":"Medium","gaps":["How CCR2 signaling engages CaSR not defined","In vitro only"]},{"year":2021,"claim":"Identified an adiponectin/APPL2-mTORC1 pathway that suppresses TNF-α-induced hepatocyte CCL2, defining a metabolic brake on chemokine-driven liver inflammation.","evidence":"Hepatocyte-specific APPL2-KO and adiponectin-KO double-KO epistasis on high-fat diet with mTORC1 analysis","pmids":["34162682"],"confidence":"High","gaps":["Transcription factor endpoint downstream of mTORC1 at the Ccl2 promoter not identified","Mechanism of mTORC1-CCL2 link not detailed"]},{"year":2023,"claim":"Demonstrated hepatocyte-intrinsic Notch/RBPJ transactivation of the Ccl2 promoter as a driver of monocyte-derived macrophage recruitment and fibrosis in NASH, with cell-specific genetic and pharmacological proof.","evidence":"Hepatocyte-specific Ccl2-KO and Notch gain-of-function mice, CCR2 inhibitor, RBPJ promoter site analysis, and NASH fibrosis histology","pmids":["36752206"],"confidence":"High","gaps":["Interaction of Notch/RBPJ with other CCL2 regulators not mapped","Human relevance shown only at promoter conservation level"]},{"year":null,"claim":"How CCL2's distinct functional outputs—adhesion, chemotaxis, parenchymal cytoprotection, osteoclast/mural cell programs—are selected at the level of receptor coupling and effector choice remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural basis for biased CCR2 signaling defined","Whether non-CCR2 receptors mediate adhesion and cytoprotection not established","In vivo significance of lipoprotein-bound CCL2 delivery not quantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,2,9,18]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[10]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[11,18]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,11,18]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,4,15]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,11,21,22,18]}],"complexes":[],"partners":["CCR2","OXLDL","LP(A)"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P13500","full_name":"C-C motif chemokine 2","aliases":["HC11","Monocyte chemoattractant protein 1","Monocyte chemotactic and activating factor","MCAF","Monocyte chemotactic protein 1","MCP-1","Monocyte secretory protein JE","Small-inducible cytokine A2"],"length_aa":99,"mass_kda":11.0,"function":"Acts as a ligand for C-C chemokine receptor CCR2 (PubMed:10529171, PubMed:10587439, PubMed:9837883). Signals through binding and activation of CCR2 and induces a strong chemotactic response and mobilization of intracellular calcium ions (PubMed:10587439, PubMed:9837883). Exhibits a chemotactic activity for monocytes and basophils but not neutrophils or eosinophils (PubMed:8195247, PubMed:8627182, PubMed:9792674). May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis (PubMed:8107690)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P13500/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL2","total_profiled":1310},"omim":[{"mim_id":"621526","title":"GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE-LIKE PROTEIN; QPCTL","url":"https://www.omim.org/entry/621526"},{"mim_id":"620874","title":"ADHESION G PROTEIN-COUPLED RECEPTOR F5; ADGRF5","url":"https://www.omim.org/entry/620874"},{"mim_id":"619991","title":"LIVER DISEASE, SEVERE CONGENITAL; SCOLIV","url":"https://www.omim.org/entry/619991"},{"mim_id":"616761","title":"SUSHI DOMAIN-CONTAINING PROTEIN 6; SUSD6","url":"https://www.omim.org/entry/616761"},{"mim_id":"616709","title":"ALPHA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE; A4GNT","url":"https://www.omim.org/entry/616709"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"urinary bladder","ntpm":701.0}],"url":"https://www.proteinatlas.org/search/CCL2"},"hgnc":{"alias_symbol":["MCP1","MCP-1","MCAF","SMC-CF","GDCF-2","HC11","MGC9434"],"prev_symbol":["SCYA2"]},"alphafold":{"accession":"P13500","domains":[{"cath_id":"2.40.50.40","chopping":"34-99","consensus_level":"medium","plddt":93.1655,"start":34,"end":99}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P13500","model_url":"https://alphafold.ebi.ac.uk/files/AF-P13500-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P13500-F1-predicted_aligned_error_v6.png","plddt_mean":86.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL2","jax_strain_url":"https://www.jax.org/strain/search?query=CCL2"},"sequence":{"accession":"P13500","fasta_url":"https://rest.uniprot.org/uniprotkb/P13500.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P13500/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P13500"}},"corpus_meta":[{"pmid":"19441883","id":"PMC_19441883","title":"Monocyte chemoattractant protein-1 (MCP-1): an overview.","date":"2009","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/19441883","citation_count":3078,"is_preprint":false},{"pmid":"10227295","id":"PMC_10227295","title":"MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions.","date":"1999","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10227295","citation_count":1013,"is_preprint":false},{"pmid":"34233864","id":"PMC_34233864","title":"MCP-1: Function, regulation, and involvement in disease.","date":"2021","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34233864","citation_count":702,"is_preprint":false},{"pmid":"2186747","id":"PMC_2186747","title":"Human monocyte chemoattractant protein-1 (MCP-1).","date":"1990","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/2186747","citation_count":580,"is_preprint":false},{"pmid":"18190912","id":"PMC_18190912","title":"Increased MCP-1 and microglia in various regions of the human alcoholic brain.","date":"2007","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18190912","citation_count":428,"is_preprint":false},{"pmid":"20633546","id":"PMC_20633546","title":"MCP-1: chemoattractant with a role beyond immunity: a review.","date":"2010","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20633546","citation_count":385,"is_preprint":false},{"pmid":"12495638","id":"PMC_12495638","title":"The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE).","date":"2003","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12495638","citation_count":353,"is_preprint":false},{"pmid":"20681057","id":"PMC_20681057","title":"The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases.","date":"2010","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/20681057","citation_count":340,"is_preprint":false},{"pmid":"22766373","id":"PMC_22766373","title":"Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes.","date":"2012","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/22766373","citation_count":314,"is_preprint":false},{"pmid":"11485904","id":"PMC_11485904","title":"Wound healing in MIP-1alpha(-/-) and MCP-1(-/-) mice.","date":"2001","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11485904","citation_count":262,"is_preprint":false},{"pmid":"8616572","id":"PMC_8616572","title":"Increased MCP-1, RANTES, and MIP-1alpha in bronchoalveolar lavage fluid of allergic asthmatic patients.","date":"1996","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8616572","citation_count":257,"is_preprint":false},{"pmid":"11756323","id":"PMC_11756323","title":"Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation.","date":"2002","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/11756323","citation_count":245,"is_preprint":false},{"pmid":"19566488","id":"PMC_19566488","title":"Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications.","date":"2009","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/19566488","citation_count":242,"is_preprint":false},{"pmid":"12753088","id":"PMC_12753088","title":"MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis.","date":"2003","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12753088","citation_count":242,"is_preprint":false},{"pmid":"29375123","id":"PMC_29375123","title":"The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally?","date":"2018","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29375123","citation_count":227,"is_preprint":false},{"pmid":"11424873","id":"PMC_11424873","title":"MCP-1 and RANTES are mediators of acute and chronic inflammation.","date":"2001","source":"Allergy and asthma proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/11424873","citation_count":219,"is_preprint":false},{"pmid":"12851645","id":"PMC_12851645","title":"Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung.","date":"2003","source":"Microcirculation (New York, N.Y. : 1994)","url":"https://pubmed.ncbi.nlm.nih.gov/12851645","citation_count":209,"is_preprint":false},{"pmid":"9185504","id":"PMC_9185504","title":"MCP-1 protects mice in lethal endotoxemia.","date":"1997","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9185504","citation_count":208,"is_preprint":false},{"pmid":"16609683","id":"PMC_16609683","title":"The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease.","date":"2006","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/16609683","citation_count":178,"is_preprint":false},{"pmid":"9372648","id":"PMC_9372648","title":"Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge.","date":"1997","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9372648","citation_count":165,"is_preprint":false},{"pmid":"21729288","id":"PMC_21729288","title":"CCL2/MCP-1 modulation of microglial activation and proliferation.","date":"2011","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/21729288","citation_count":159,"is_preprint":false},{"pmid":"17625118","id":"PMC_17625118","title":"Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice.","date":"2007","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/17625118","citation_count":153,"is_preprint":false},{"pmid":"24862889","id":"PMC_24862889","title":"Impact of MCP-1 in atherosclerosis.","date":"2014","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/24862889","citation_count":144,"is_preprint":false},{"pmid":"10469372","id":"PMC_10469372","title":"Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats.","date":"1999","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/10469372","citation_count":141,"is_preprint":false},{"pmid":"19129402","id":"PMC_19129402","title":"Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline.","date":"2009","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19129402","citation_count":124,"is_preprint":false},{"pmid":"10886563","id":"PMC_10886563","title":"MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy.","date":"2000","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/10886563","citation_count":124,"is_preprint":false},{"pmid":"21071523","id":"PMC_21071523","title":"MCP-1 gene activation marks acute kidney injury.","date":"2010","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/21071523","citation_count":121,"is_preprint":false},{"pmid":"11786090","id":"PMC_11786090","title":"Oxalate ions and calcium oxalate crystals stimulate MCP-1 expression by renal epithelial cells.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/11786090","citation_count":119,"is_preprint":false},{"pmid":"10489845","id":"PMC_10489845","title":"Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics.","date":"1999","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/10489845","citation_count":118,"is_preprint":false},{"pmid":"10469367","id":"PMC_10469367","title":"MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis.","date":"1999","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/10469367","citation_count":117,"is_preprint":false},{"pmid":"9763529","id":"PMC_9763529","title":"Estradiol suppresses MCP-1 expression In vivo : implications for atherosclerosis.","date":"1998","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9763529","citation_count":114,"is_preprint":false},{"pmid":"11751168","id":"PMC_11751168","title":"MCP-1 causes leukocyte recruitment and subsequently endotoxemic ileus in rat.","date":"2002","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11751168","citation_count":106,"is_preprint":false},{"pmid":"11149670","id":"PMC_11149670","title":"Neuronal MCP-1 expression in response to remote nerve injury.","date":"2001","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11149670","citation_count":101,"is_preprint":false},{"pmid":"29594759","id":"PMC_29594759","title":"MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis.","date":"2018","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/29594759","citation_count":90,"is_preprint":false},{"pmid":"33782965","id":"PMC_33782965","title":"The molecular structure and role of CCL2 (MCP-1) and C-C chemokine receptor CCR2 in skeletal biology and diseases.","date":"2021","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33782965","citation_count":89,"is_preprint":false},{"pmid":"18442784","id":"PMC_18442784","title":"Role of MCP-1 in endotoxemia and sepsis.","date":"2008","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18442784","citation_count":87,"is_preprint":false},{"pmid":"11980865","id":"PMC_11980865","title":"MCP-1 expression in endotoxin-induced uveitis.","date":"2002","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/11980865","citation_count":87,"is_preprint":false},{"pmid":"23667177","id":"PMC_23667177","title":"MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma.","date":"2013","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23667177","citation_count":86,"is_preprint":false},{"pmid":"9365123","id":"PMC_9365123","title":"Role of MCP-1 and RANTES in inflammation and progression to fibrosis during murine crescentic nephritis.","date":"1997","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9365123","citation_count":85,"is_preprint":false},{"pmid":"23547114","id":"PMC_23547114","title":"IκBζ is a transcriptional key regulator of CCL2/MCP-1.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23547114","citation_count":84,"is_preprint":false},{"pmid":"29976212","id":"PMC_29976212","title":"Role of MCP-1 and CCR2 in ethanol-induced neuroinflammation and neurodegeneration in the developing brain.","date":"2018","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/29976212","citation_count":83,"is_preprint":false},{"pmid":"21115617","id":"PMC_21115617","title":"MCP-1 contributes to arteriovenous fistula failure.","date":"2010","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/21115617","citation_count":83,"is_preprint":false},{"pmid":"27069796","id":"PMC_27069796","title":"Aging and serum MCP-1 are associated with gut microbiome composition in a murine model.","date":"2016","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/27069796","citation_count":83,"is_preprint":false},{"pmid":"10905466","id":"PMC_10905466","title":"Increased expression of chemokines (MCP-1, MIP-1alpha, RANTES) after peripheral nerve transection.","date":"2000","source":"Journal of the peripheral nervous system : JPNS","url":"https://pubmed.ncbi.nlm.nih.gov/10905466","citation_count":82,"is_preprint":false},{"pmid":"14752027","id":"PMC_14752027","title":"Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation.","date":"2004","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/14752027","citation_count":82,"is_preprint":false},{"pmid":"17692033","id":"PMC_17692033","title":"MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy.","date":"2007","source":"Inflammation & allergy drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/17692033","citation_count":80,"is_preprint":false},{"pmid":"19364494","id":"PMC_19364494","title":"MCP-1 expressed by osteoclasts stimulates osteoclastogenesis in an autocrine/paracrine manner.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19364494","citation_count":79,"is_preprint":false},{"pmid":"9500525","id":"PMC_9500525","title":"Synergistic induction of MCP-1 and -2 by IL-1beta and interferons in fibroblasts and epithelial cells.","date":"1998","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9500525","citation_count":73,"is_preprint":false},{"pmid":"24420912","id":"PMC_24420912","title":"Exosomal ATF3 RNA attenuates pro-inflammatory gene MCP-1 transcription in renal ischemia-reperfusion.","date":"2014","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24420912","citation_count":71,"is_preprint":false},{"pmid":"8622597","id":"PMC_8622597","title":"Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells.","date":"1996","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/8622597","citation_count":70,"is_preprint":false},{"pmid":"14512159","id":"PMC_14512159","title":"Cytokine regulation of MCP-1 expression in brain and retinal microvascular endothelial cells.","date":"2003","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/14512159","citation_count":70,"is_preprint":false},{"pmid":"36752206","id":"PMC_36752206","title":"Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36752206","citation_count":68,"is_preprint":false},{"pmid":"18296557","id":"PMC_18296557","title":"Role of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages.","date":"2008","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18296557","citation_count":68,"is_preprint":false},{"pmid":"38239353","id":"PMC_38239353","title":"Role of MCP-1 as an inflammatory biomarker in nephropathy.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38239353","citation_count":66,"is_preprint":false},{"pmid":"22739135","id":"PMC_22739135","title":"MCP-1 induced protein promotes adipogenesis via oxidative stress, endoplasmic reticulum stress and autophagy.","date":"2012","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22739135","citation_count":66,"is_preprint":false},{"pmid":"30472461","id":"PMC_30472461","title":"Role of MCP-1 and CCR2 in alcohol neurotoxicity.","date":"2018","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/30472461","citation_count":61,"is_preprint":false},{"pmid":"20193755","id":"PMC_20193755","title":"Elevated expression of MCP-1, IL-2 and PTPR-N in basal ganglia of Tourette syndrome cases.","date":"2010","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/20193755","citation_count":61,"is_preprint":false},{"pmid":"20110124","id":"PMC_20110124","title":"Dual delivery of VEGF and MCP-1 to support endothelial cell transplantation for therapeutic vascularization.","date":"2010","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/20110124","citation_count":61,"is_preprint":false},{"pmid":"29340098","id":"PMC_29340098","title":"ICAM-1 regulates macrophage polarization by suppressing MCP-1 expression via miR-124 upregulation.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29340098","citation_count":58,"is_preprint":false},{"pmid":"24222114","id":"PMC_24222114","title":"MCP-1 promotes invasion and adhesion of human ovarian cancer cells.","date":"2013","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24222114","citation_count":57,"is_preprint":false},{"pmid":"16102724","id":"PMC_16102724","title":"MCP-1/CCL2 protects cardiac myocytes from hypoxia-induced apoptosis by a G(alphai)-independent pathway.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16102724","citation_count":56,"is_preprint":false},{"pmid":"18383340","id":"PMC_18383340","title":"Increase of MCP-1 (CCL2) in myelin mutant Schwann cells is mediated by MEK-ERK signaling pathway.","date":"2008","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/18383340","citation_count":56,"is_preprint":false},{"pmid":"9225989","id":"PMC_9225989","title":"MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression.","date":"1997","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9225989","citation_count":55,"is_preprint":false},{"pmid":"24881026","id":"PMC_24881026","title":"The effect of inflammatory cell-derived MCP-1 loss on neuronal survival during chronic neuroinflammation.","date":"2014","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/24881026","citation_count":54,"is_preprint":false},{"pmid":"20406462","id":"PMC_20406462","title":"Regulation of MCP-1 chemokine transcription by p53.","date":"2010","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20406462","citation_count":53,"is_preprint":false},{"pmid":"11949821","id":"PMC_11949821","title":"MCP-1 expression in CNS-1 astrocytoma cells: implications for macrophage infiltration into tumors in vivo.","date":"2002","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11949821","citation_count":51,"is_preprint":false},{"pmid":"16488443","id":"PMC_16488443","title":"MCP-1 parallels inflammatory and regenerative responses in ischemic muscle.","date":"2006","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/16488443","citation_count":50,"is_preprint":false},{"pmid":"21529952","id":"PMC_21529952","title":"Endogenous MCP-1 promotes lung inflammation induced by LPS and LTA.","date":"2011","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21529952","citation_count":49,"is_preprint":false},{"pmid":"27278779","id":"PMC_27278779","title":"Urinary MCP-1 as a biomarker for lupus nephritis: a meta-analysis.","date":"2017","source":"Zeitschrift fur Rheumatologie","url":"https://pubmed.ncbi.nlm.nih.gov/27278779","citation_count":48,"is_preprint":false},{"pmid":"25555372","id":"PMC_25555372","title":"MCP-1 stimulates spinal microglia via PI3K/Akt pathway in bone cancer pain.","date":"2014","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/25555372","citation_count":48,"is_preprint":false},{"pmid":"21714842","id":"PMC_21714842","title":"MCP-1 and IL-8 as pain biomarkers in fibromyalgia: a pilot study.","date":"2011","source":"Pain medicine (Malden, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/21714842","citation_count":46,"is_preprint":false},{"pmid":"1755379","id":"PMC_1755379","title":"Biological aspects of monocyte chemoattractant protein-1 (MCP-1).","date":"1991","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/1755379","citation_count":45,"is_preprint":false},{"pmid":"17977946","id":"PMC_17977946","title":"MCP-1 targeting inhibits muscularis macrophage recruitment and intestinal smooth muscle dysfunction in colonic inflammation.","date":"2007","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17977946","citation_count":45,"is_preprint":false},{"pmid":"12787135","id":"PMC_12787135","title":"17Beta-estradiol inhibits MCP-1 production in human keratinocytes.","date":"2003","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12787135","citation_count":45,"is_preprint":false},{"pmid":"33974569","id":"PMC_33974569","title":"Urinary EGF and MCP-1 and risk of CKD after cardiac surgery.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/33974569","citation_count":44,"is_preprint":false},{"pmid":"14962280","id":"PMC_14962280","title":"Adult porcine islets produce MCP-1 and recruit human monocytes in vitro.","date":"2004","source":"Xenotransplantation","url":"https://pubmed.ncbi.nlm.nih.gov/14962280","citation_count":44,"is_preprint":false},{"pmid":"12234296","id":"PMC_12234296","title":"Expression of the chemokines MCP-1/CCL2 and RANTES/CCL5 is differentially regulated by infiltrating inflammatory cells.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/12234296","citation_count":43,"is_preprint":false},{"pmid":"19215923","id":"PMC_19215923","title":"Soy phosphatidylcholine inhibited TLR4-mediated MCP-1 expression in vascular cells.","date":"2009","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/19215923","citation_count":43,"is_preprint":false},{"pmid":"22750227","id":"PMC_22750227","title":"RANTES, MCP-1 chemokines and factors describing rheumatoid arthritis.","date":"2012","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22750227","citation_count":42,"is_preprint":false},{"pmid":"20385066","id":"PMC_20385066","title":"Impact of RANTES, MCP-1 and IL-8 in mast cells.","date":"2010","source":"Journal of biological regulators and homeostatic agents","url":"https://pubmed.ncbi.nlm.nih.gov/20385066","citation_count":41,"is_preprint":false},{"pmid":"12758167","id":"PMC_12758167","title":"Regulation of MCP-1 gene transcription by Smads and HIV-1 Tat in human glial cells.","date":"2003","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/12758167","citation_count":40,"is_preprint":false},{"pmid":"32218781","id":"PMC_32218781","title":"Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32218781","citation_count":38,"is_preprint":false},{"pmid":"23480385","id":"PMC_23480385","title":"MCP-1 in psoriatic patients: effect of biological therapy.","date":"2013","source":"The Journal of dermatological treatment","url":"https://pubmed.ncbi.nlm.nih.gov/23480385","citation_count":38,"is_preprint":false},{"pmid":"26014148","id":"PMC_26014148","title":"Role of MCP-1 in alcohol-induced aggressiveness of colorectal cancer cells.","date":"2015","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/26014148","citation_count":38,"is_preprint":false},{"pmid":"34162682","id":"PMC_34162682","title":"Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage Infiltration.","date":"2021","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/34162682","citation_count":38,"is_preprint":false},{"pmid":"34868363","id":"PMC_34868363","title":"MCP-1 targeting: Shutting off an engine for tumor development.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/34868363","citation_count":37,"is_preprint":false},{"pmid":"10506949","id":"PMC_10506949","title":"Regulated expression of MCP-1 by osteoblastic cells in vitro and in vivo.","date":"1999","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/10506949","citation_count":36,"is_preprint":false},{"pmid":"31137011","id":"PMC_31137011","title":"MCP-1 deficiency enhances browning of adipose tissue via increased M2 polarization.","date":"2019","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31137011","citation_count":36,"is_preprint":false},{"pmid":"29304171","id":"PMC_29304171","title":"MCP-1, KC-like and IL-8 as critical mediators of pathogenesis caused by Babesia canis.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29304171","citation_count":36,"is_preprint":false},{"pmid":"12724308","id":"PMC_12724308","title":"Protein kinase C beta is required for human monocyte chemotaxis to MCP-1.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12724308","citation_count":36,"is_preprint":false},{"pmid":"15389752","id":"PMC_15389752","title":"MCP-1 gene (SCYA2) and schizophrenia: a case-control association study.","date":"2005","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15389752","citation_count":35,"is_preprint":false},{"pmid":"20855682","id":"PMC_20855682","title":"Plasma levels of MCP-1 and adiponectin in obstructive sleep apnea syndrome.","date":"2010","source":"Archives of otolaryngology--head & neck surgery","url":"https://pubmed.ncbi.nlm.nih.gov/20855682","citation_count":35,"is_preprint":false},{"pmid":"31774703","id":"PMC_31774703","title":"MCP-1 mediates ischemia-reperfusion-induced cardiomyocyte apoptosis via MCPIP1 and CaSR.","date":"2019","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31774703","citation_count":34,"is_preprint":false},{"pmid":"20571857","id":"PMC_20571857","title":"MCP-1 promotes mural cell recruitment during angiogenesis in the aortic ring model.","date":"2010","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/20571857","citation_count":34,"is_preprint":false},{"pmid":"33803115","id":"PMC_33803115","title":"MCP-1 Predicts Recurrent Cardiovascular Events in Patients with Persistent Inflammation.","date":"2021","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33803115","citation_count":34,"is_preprint":false},{"pmid":"23996571","id":"PMC_23996571","title":"Dominant negative MCP-1 blocks human osteoclast differentiation.","date":"2014","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23996571","citation_count":33,"is_preprint":false},{"pmid":"16518329","id":"PMC_16518329","title":"Prednisolone inhibits hyperosmolarity-induced expression of MCP-1 via NF-kappaB in peritoneal mesothelial cells.","date":"2006","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/16518329","citation_count":32,"is_preprint":false},{"pmid":"20299783","id":"PMC_20299783","title":"Suppressor of cytokine signaling-1 ameliorates expression of MCP-1 in diabetic nephropathy.","date":"2010","source":"American journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/20299783","citation_count":32,"is_preprint":false},{"pmid":"20132473","id":"PMC_20132473","title":"Regulation of MCP-1 production in brain by stress and noradrenaline-modulating drugs.","date":"2010","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20132473","citation_count":31,"is_preprint":false},{"pmid":"11005777","id":"PMC_11005777","title":"Monocyte chemoattractant protein 1 (MCP-1) in temporal arteritis and polymyalgia rheumatica.","date":"2000","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/11005777","citation_count":29,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53083,"output_tokens":7560,"usd":0.136324,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16970,"output_tokens":7204,"usd":0.132475,"stage2_stop_reason":"end_turn"},"total_usd":0.268799,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"MCP-1 (CCL2) rapidly triggers firm adhesion of rolling monocytes to vascular endothelium under flow conditions by acting on endothelium expressing E-selectin; this effect is independent of calcium transient induction or chemotaxis, revealing a distinct adhesion-promoting mechanism separate from classical chemotaxis.\",\n      \"method\": \"Flow chamber adhesion assay with endothelial monolayers transduced to express specific leukocyte-adherence receptors; calcium imaging\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 / Strong — direct functional assay under physiological flow conditions with orthogonal measurements (adhesion, calcium, chemotaxis) dissecting mechanism; published in high-impact venue\",\n      \"pmids\": [\"10227295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CCL2/MCP-1 protects mixed cultures of human neurons and astrocytes from NMDA- or HIV-Tat-induced apoptosis by reducing extracellular glutamate levels and NMDA receptor 1 (NMDAR1) expression, and by decreasing intracellular Tat; the protective effect of RANTES was blocked by anti-MCP-1 antibody, indicating RANTES acts via induction of MCP-1.\",\n      \"method\": \"Cell culture apoptosis assay, extracellular glutamate measurement, NMDAR1 Western blot, anti-MCP-1 neutralizing antibody blockade, NMDA receptor blocker MK801\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in one study, single lab, in vitro model\",\n      \"pmids\": [\"12753088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PKCβ isoform is specifically required for MCP-1-induced chemotaxis of human monocytes; antisense knockdown of PKCβ caused ~89% inhibition of chemotaxis without affecting the MCP-1/CCR2-triggered calcium signal, placing PKCβ downstream of the initial receptor-calcium response in the chemotactic signaling cascade.\",\n      \"method\": \"Antisense oligodeoxyribonucleotide knockdown of specific PKC isoforms; PKC pharmacological inhibitors (GF109203X, Calphostin C); chemotaxis assay; calcium response measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — isoform-specific antisense knockdown combined with pharmacological inhibition and calcium signaling dissection in one study\",\n      \"pmids\": [\"12724308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TGF-β1 inhibition of MCP-1 expression in macrophages is mediated specifically by Smad3; Smad3 overexpression potently repressed inducible MCP-1 expression, and TGF-β1 inhibition of cytokine-induced MCP-1 was completely lost in Smad3-deficient macrophages. Mechanistically, Smad3 antagonizes AP-1 (c-Jun/c-Fos) DNA binding and activity at the MCP-1 promoter.\",\n      \"method\": \"Adenoviral Smad3 overexpression; Smad3-knockout macrophages; AP-1 DNA-protein binding assay; cardiac allograft model with accelerated arteriopathy in Smad3-KO mice\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic knockout plus gain-of-function with mechanistic AP-1 binding assay in one study, in vitro and in vivo validation\",\n      \"pmids\": [\"14752027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCL2/MCP-1 protects cardiac myocytes from hypoxia-induced apoptosis through ERK1/2 signaling (not through Gαi, which mediates monocyte chemotaxis); CCL2 treatment decreased caspase-3 activation and JNK/SAPK phosphorylation, increased Bcl-xL and Bag-1, and decreased Bax, demonstrating cytoprotection and chemotaxis use distinct signaling pathways.\",\n      \"method\": \"Cardiac myocyte hypoxia apoptosis assay; ERK1/2 pathway inhibitor; Gαi inhibitor (pertussis toxin); Western blot for Bcl-2 family proteins, caspase-3, JNK/SAPK\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple signaling pathway dissections in one study, single lab, in vitro model\",\n      \"pmids\": [\"16102724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MCP-1 (CCL2) upregulation in P0-mutant (myelin-deficient) Schwann cells is mediated by the MEK1/2–ERK1/2 signaling pathway; MEK1/2 inhibitor CI-1040 reduced ERK1/2 phosphorylation and MCP-1 expression in Schwann cell lines in vitro and in peripheral nerves of P0+/− mice in vivo.\",\n      \"method\": \"Western blot of peripheral nerve lysates for phospho-ERK1/2 and phospho-MEK1/2; MEK1/2 inhibitor CI-1040 in vitro and systemic in vivo treatment; MCP-1 ELISA\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway inhibition with in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"18383340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"12(S)-HETE (a 12/15-lipoxygenase product) increases MCP-1 mRNA and protein expression in macrophages via PKC, p38 MAPK, and NADPH oxidase activity; genetic knockout of 12/15-LO reduced macrophage MCP-1 expression, while overexpression increased it.\",\n      \"method\": \"12/15-LO knockout and transgenic mice; stable 12/15-LO overexpressing macrophage cell line; pharmacological inhibitors of PKC, p38, and NADPH oxidase; MCP-1 ELISA and RT-PCR\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic gain/loss-of-function plus pharmacological dissection of three parallel signaling nodes, replicated across multiple models\",\n      \"pmids\": [\"18296557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Noradrenaline induces MCP-1 expression in astrocytes via β2-adrenergic receptor and cAMP signaling, and this astrocyte-derived MCP-1 reduces NMDA-dependent glutamate release and Ca2+ entry in neurons, thereby mediating neuroprotection; neutralizing antibody to MCP-1 blocked conditioned medium-mediated protection, and MCP-1 dose-dependently reduced neuronal damage from NMDA, glutamate, and oxygen-glucose deprivation.\",\n      \"method\": \"Primary astrocyte and neuron cultures; MCP-1 promoter-luciferase reporter; β2-adrenergic receptor antagonist; cAMP analog; neutralizing anti-MCP-1 antibody; intracellular Ca2+ measurement; LDH release assay; ATP measurement; oxygen-glucose deprivation model\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — promoter reporter, receptor pharmacology, antibody neutralization, and multiple functional readouts in one study\",\n      \"pmids\": [\"19129402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MCP-1 expressed by osteoclasts stimulates osteoclastogenesis in an autocrine/paracrine manner under RANKL stimulation; MCP-1-deficient osteoclast precursors showed impaired multinuclear osteoclast formation, downregulation of DC-STAMP, NFATc1, and cathepsin K, and these defects were rescued by recombinant MCP-1 but not by rescuing DC-STAMP, indicating MCP-1 acts upstream of DC-STAMP in the osteoclastogenesis pathway.\",\n      \"method\": \"MCP-1 knockout mouse osteoclast cultures; recombinant MCP-1 rescue; DC-STAMP-deficient mouse cells; RT-PCR for osteoclast differentiation markers\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus recombinant protein rescue with epistasis experiment, single lab\",\n      \"pmids\": [\"19364494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MCP-1 promotes mural cell recruitment during angiogenesis; angiopoietin-1-induced mural cell recruitment requires MCP-1 (anti-MCP-1 antibody blocks Ang-1 effect), and aortic rings from MCP-1-knockout or CCR2-knockout mice have fewer mural cells; recombinant MCP-1 dose-dependently increases mural cell number.\",\n      \"method\": \"Aortic ring angiogenesis model; MCP-1 and CCR2 knockout mice; anti-MCP-1 blocking antibody; recombinant MCP-1 addition; p38 MAPK inhibitor\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO (two genes), antibody neutralization, and recombinant protein gain-of-function all converge on same conclusion\",\n      \"pmids\": [\"20571857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MCP-1 binds to oxidized LDL (OxLDL) via basic amino acid residues Arg-18 and Lys-19; mutation of these residues abolished OxLDL binding. OxLDL-bound MCP-1 retains monocyte-recruiting activity. MCP-1 also binds Lp(a) in human plasma through oxidized phospholipids (OxPLs), as demonstrated by E06 monoclonal antibody (anti-OxPL) inhibition.\",\n      \"method\": \"Site-directed mutagenesis (Arg18Ala/Lys19Ala); OxLDL binding assay; E06 monoclonal antibody inhibition; recombinant MCP-1 spiking into human plasma; Lp(a) capture and MCP-1 ELISA; monocyte migration assay\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis identifying binding residues combined with antibody blockade and in vivo plasma binding experiments\",\n      \"pmids\": [\"23667177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IκBζ, an atypical IκB family member, is a key transcriptional activator of the Ccl2 (MCP-1) gene; IκBζ-deficient macrophages show impaired CCL2 secretion in response to LPS or peptidoglycan, IκBζ is directly recruited to the proximal Ccl2 promoter (by ChIP), and promotes transcription-enhancing H3K4me3 histone marks. In vivo, IκBζ-KO mice show impaired CCL2 secretion and monocyte infiltration in peritonitis.\",\n      \"method\": \"IκBζ-knockout macrophages; ELISA for CCL2; chromatin immunoprecipitation (ChIP) for IκBζ occupancy and H3K4me3; in vivo peritonitis model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic KO, ChIP demonstrating direct promoter binding, histone mark analysis, and in vivo validation in one study\",\n      \"pmids\": [\"23547114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ATF3 binds ATF/CRE sites in the MCP-1 promoter and transcriptionally represses MCP-1 expression in renal epithelial cells after ischemia/reperfusion (I/R) injury; ATF3-knockout mice showed higher MCP-1 induction after I/R. Exosomal ATF3 RNA from epithelial cells also inhibited MCP-1 expression and macrophage migration.\",\n      \"method\": \"ATF3 knockout mice; I/R injury model; chromatin immunoprecipitation/promoter binding assay for ATF3 at MCP-1 promoter; exosome isolation and transfer; MCP-1 ELISA; macrophage migration assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and direct promoter binding shown, single lab with in vitro and in vivo components\",\n      \"pmids\": [\"24420912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MCP-1 promotes invasion and adhesion of human ovarian cancer (SKOV-3) cells via CCR2; CCR2 antagonist blocked MCP-1-induced invasion and adhesion, and CCR2 expression was confirmed in SKOV-3 cells.\",\n      \"method\": \"Transwell invasion assay; cell adhesion assay; CCR2 antagonist treatment; immunohistochemistry for CCR2\",\n      \"journal\": \"Anticancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, receptor antagonist only, in vitro model\",\n      \"pmids\": [\"24222114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MCP-1 stimulates spinal microglia via the PI3K/Akt pathway in bone cancer pain; intrathecal anti-MCP-1 antibody or PI3K inhibitor LY294002 reduced p-Akt and OX-42 expression in spinal dorsal horns, and LY294002 attenuated mechanical allodynia.\",\n      \"method\": \"Bone cancer pain rat model; in vitro microglia stimulation with recombinant MCP-1; Western blot for p-Akt and OX-42; pharmacological PI3K inhibitor; intrathecal anti-MCP-1 neutralizing antibody; behavioral pain testing\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo pharmacological dissection with behavioral readout, single lab\",\n      \"pmids\": [\"25555372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MCP-1 drives triple-negative breast cancer cell invasion via the CCR2 receptor and MAP kinase (MEK/ERK) pathway; CCR2 antagonist and MEK inhibitor U0126 both blocked MCP-1-induced invasion; MCP-1 knockdown in BT-549 cells decreased invasion and downregulated EMT markers N-cadherin and vimentin.\",\n      \"method\": \"Boyden chamber invasion assay; CCR2 antagonist; MEK inhibitor U0126; siRNA knockdown of MCP-1; qRT-PCR and ELISA for MCP-1; Western blot for EMT markers\",\n      \"journal\": \"Breast cancer research and treatment\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic (siRNA) approaches with multiple downstream readouts, single lab\",\n      \"pmids\": [\"29594759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MCP-1/CCR2 signaling mediates ethanol-induced microglial activation/neuroinflammation and neuroapoptosis in the developing brain; MCP-1-KO and CCR2-KO mice were more resistant to ethanol-induced neuroapoptosis; MCP-1 inhibitor (Bindarit) and CCR2 antagonist (RS504393) reduced neuroinflammation; mechanistically, blocking MCP-1/CCR2 attenuated ethanol-induced activation of TLR4 and GSK3β.\",\n      \"method\": \"MCP-1-KO and CCR2-KO mice; ethanol neonatal exposure model; immunohistochemistry and immunoblotting; neuron/microglia co-culture; pharmacological inhibitors Bindarit and RS504393; TLR4 and GSK3β signaling analysis\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — dual genetic knockout models, pharmacological inhibition, in vitro co-culture, and mechanistic signaling pathway dissection, replicated across models\",\n      \"pmids\": [\"29976212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"I/R-induced MCP-1 release regulates cardiomyocyte apoptosis via CaSR (Ca2+-sensing receptor) acting as upstream effector of MCPIP1 (MCP-1-induced protein 1), which in turn activates ER stress but not autophagy; CCR2 inhibitor RS-102895 and CaSR inhibitor NPS-2143 both reduced I/R-induced apoptosis.\",\n      \"method\": \"HL-1 cardiac cells and primary neonatal cardiomyocytes; simulated I/R; CCR2 inhibitor (RS-102895); CaSR inhibitor (NPS-2143) and activator (evocalcet); Hoechst staining and flow cytometry apoptosis; ER stress markers by Western blot; ELISA for MCP-1\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection of CaSR-MCPIP1-ER stress axis with multiple inhibitor/activator tools, single lab, in vitro\",\n      \"pmids\": [\"31774703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In NASH, hepatocyte-specific Notch signaling transactivates the Ccl2 promoter via an evolutionarily conserved Notch/RBPJ binding site, driving hepatocyte-derived MCP-1 secretion that recruits monocyte-derived macrophages and causes liver fibrosis; hepatocyte-specific Ccl2-KO reduced MoMF infiltrate and fibrosis, while forced hepatocyte MCP-1 expression caused the opposite phenotype, and CCR2 inhibitor ameliorated these effects.\",\n      \"method\": \"Hepatocyte-specific Ccl2-KO mice; hepatocyte-specific Notch gain-of-function mice; CCR2 inhibitor treatment; Ccl2 promoter analysis (RBPJ site); NASH diet mouse model; liver histology for fibrosis and macrophage markers\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — hepatocyte-specific KO and OE genetic models, promoter mechanism identified (Notch/RBPJ site), pharmacological CCR2 inhibition, in vivo fibrosis readout\",\n      \"pmids\": [\"36752206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Lysophosphatidylcholine (LPC) stimulates MCP-1 mRNA expression and protein secretion in human vascular endothelial cells (HUVECs) via protein kinase C (PKC) pathway; PKC inhibitor staurosporine attenuated LPC-induced MCP-1 mRNA increase by 53%.\",\n      \"method\": \"HUVEC cultures; LPC treatment; ELISA for MCP-1 protein; Northern blot/mRNA quantification; staurosporine (PKC inhibitor) co-treatment\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single pharmacological inhibitor approach, single lab, partial mechanistic follow-up\",\n      \"pmids\": [\"8622597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Smad-3 stimulates basal and HIV-1 Tat-mediated MCP-1 transcription in human astrocytic cells, while Smad-4 decreases both Smad-3- and Tat-induced MCP-1 promoter activity; Smad-3 and Smad-4 physically associate with the N-terminal region (residues 1–40) of Tat, and the MH2 domain of Smad-3 is required for this transcriptional cooperation.\",\n      \"method\": \"Transfection reporter assays (MCP-1 promoter-luciferase); protein-binding studies (co-association of Smad domains with Tat); domain deletion/mutation analysis of Smad\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional promoter reporter assays plus protein-protein interaction mapping with domain deletions, single lab\",\n      \"pmids\": [\"12758167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"p53 directly binds to a site ~2.5 kb upstream of the MCP-1 transcriptional start site (confirmed by EMSA and ChIP) and is required for TNF-α-induced MCP-1 transcription in keratinocytes; HPV E6-mediated p53 degradation abolishes TNF-α-induced MCP-1 expression, and siRNA against p53 decreased MCP-1 transcription, confirming a p53–MCP-1 transcriptional axis.\",\n      \"method\": \"EMSA (electrophoretic mobility shift assay); chromatin immunoprecipitation (ChIP); siRNA knockdown of p53; HPV E6/E7 expressing cell lines; temperature-sensitive p53 mutant cells; Li-Fraumeni cells\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct p53 binding shown by both EMSA and ChIP, functional siRNA knockdown, multiple genetic cell systems all converging\",\n      \"pmids\": [\"20406462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"17β-estradiol (E2) inhibits MCP-1 gene expression in keratinocytes through estrogen receptor beta (ERβ), which physically associates (co-immunoprecipitation) with Sp1 or AP-1 in an E2-dependent manner, inhibiting their transcriptional activity at the Sp1 and AP-1 elements in the MCP-1 promoter without blocking their DNA binding.\",\n      \"method\": \"MCP-1 promoter-luciferase reporter; ERβ transfection; estrogen receptor antagonist ICI 182780; Sp1 and AP-1 transcriptional activity assays; co-immunoprecipitation (ERβ with Sp1/AP-1); ERβ domain deletion/mutation analysis\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — promoter reporter assay, co-IP for protein interaction, receptor domain mutagenesis, and multiple transcription factor dissections in one study\",\n      \"pmids\": [\"12787135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Dominant negative MCP-1 (7ND) blocks human osteoclast differentiation by preventing early induction of calmodulin 1 (CALM1), JUN, and NFATc2; MCP-1 mRNA was induced >1000-fold within 24 h of RANKL treatment, preceding induction of NFATc1, NFATc2, cathepsin K, and TRAP, placing MCP-1 induction at the apex of the RANKL-driven osteoclastogenesis cascade.\",\n      \"method\": \"Human cord blood CFU-GM differentiation to osteoclasts; quantitative PCR for multiple osteoclast markers over time course; dominant negative MCP-1 (7ND) treatment; temporal gene expression profiling\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant negative inhibition with comprehensive temporal gene expression profiling establishing pathway ordering, single lab\",\n      \"pmids\": [\"23996571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Adiponectin suppresses TNF-α-stimulated MCP-1 expression in hepatocytes via the APPL2-mTORC1 signaling axis; hepatocyte-specific APPL2 knockout enhanced adiponectin sensitivity, blocked TNF-α-induced MCP-1 expression, and reduced macrophage infiltration and hepatic inflammation, while concomitant adiponectin knockout reversed these effects.\",\n      \"method\": \"Hepatocyte-specific APPL2 KO mice; adiponectin KO mice; double KO strategy; high-fat diet model; mTORC1 signaling analysis; macrophage infiltration histology; MCP-1 ELISA\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — dual genetic KO epistasis (APPL2 and adiponectin) with pathway (mTORC1) identification and in vivo macrophage infiltration readout\",\n      \"pmids\": [\"34162682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"High-glucose/hyperosmolarity-induced MCP-1 expression in peritoneal mesothelial cells is mediated by PKC activation and downstream NF-κB (not by MEK/ERK, p38 MAPK, or JNK); prednisolone inhibited NF-κB DNA binding and MCP-1 expression by increasing IκBα, and this effect was reversed by a glucocorticoid receptor antagonist.\",\n      \"method\": \"Rat peritoneal mesothelial cells; high-glucose/mannitol treatment; pharmacological inhibitors of PKC, NF-κB, MEK, p38, JNK; EMSA for NF-κB binding; Western blot; MCP-1 RT-PCR and ELISA; glucocorticoid receptor antagonist mifepristone\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic pharmacological dissection of multiple signaling pathways with EMSA confirmation, single lab\",\n      \"pmids\": [\"16518329\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL2/MCP-1 is a CC chemokine secreted by diverse cell types that functions primarily through its G-protein-coupled receptor CCR2 to recruit monocytes and macrophages to sites of inflammation; its chemotactic signaling requires PKCβ downstream of the receptor-calcium signal, while separate ERK1/2-dependent pathways mediate cytoprotection in neurons and cardiomyocytes; MCP-1 transcription is regulated by multiple mechanisms including NF-κB/IκBζ co-activation, direct p53 binding to the promoter, Smad3-mediated AP-1 antagonism downstream of TGF-β, Notch/RBPJ transactivation in hepatocytes, ERβ–Sp1/AP-1 inhibition by estradiol, and MEK-ERK-dependent upregulation in Schwann cells; MCP-1 also binds oxidized LDL and Lp(a) via Arg-18/Lys-19 residues and retains monocyte-recruiting activity in this lipid-bound form, acts autocrine/paracrine to support osteoclastogenesis upstream of DC-STAMP and NFATc1, and mediates mural cell recruitment during angiogenesis downstream of angiopoietin-1/p38 MAPK.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CCL2/MCP-1 is a secreted CC chemokine that orchestrates myeloid cell recruitment in inflammation, acting primarily through its receptor CCR2 to drive monocyte/macrophage chemotaxis, adhesion, and tissue infiltration [#0, #18]. Under vascular flow it triggers firm adhesion of rolling monocytes to E-selectin-bearing endothelium, a function dissociable from calcium signaling and chemotaxis [#0]; in the chemotactic arm, CCR2 engagement signals through a calcium transient and a downstream PKCβ requirement that is genetically separable from the receptor-calcium step itself [#2]. CCL2 also binds oxidized LDL and Lp(a) via its basic residues Arg-18/Lys-19 while retaining monocyte-recruiting activity, linking the chemokine to lipoprotein-associated inflammation [#10]. Beyond leukocyte trafficking, CCL2/CCR2 supports osteoclastogenesis, acting upstream of DC-STAMP, NFATc1, calmodulin 1, JUN and NFATc2 at the apex of RANKL-driven differentiation [#8, #23], and mediates angiopoietin-1-dependent mural cell recruitment during angiogenesis [#9]. In parenchymal cells the chemokine engages a distinct, Gαi-independent ERK1/2 program that is cytoprotective in cardiomyocytes and neurons, lowering glutamate/NMDAR1-dependent excitotoxicity and apoptosis [#4, #7, #1]. CCL2 transcription is a highly regulated convergence point: it is positively driven by the atypical IκB family member IκBζ recruited to the proximal Ccl2 promoter with H3K4me3 deposition [#11], by direct p53 binding required for TNF-α induction [#21], and by Notch/RBPJ transactivation in hepatocytes that fuels macrophage recruitment and fibrosis in NASH [#18]; it is repressed by TGF-β1/Smad3 antagonism of AP-1 [#3], by ATF3 binding ATF/CRE sites [#12], and by estradiol-activated ERβ that sequesters Sp1/AP-1 activity [#22]. CCL2 contributes to inflammatory and pathological signaling in cancer invasion, neuroinflammatory pain, ethanol-induced developmental neuroapoptosis, and ischemia/reperfusion injury, generally through CCR2 and MAPK or PI3K/Akt effectors [#16, #15, #14, #17].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that CCL2 has an adhesion-promoting function on endothelium that is mechanistically distinct from its classical chemotactic role, expanding its action beyond chemotaxis.\",\n      \"evidence\": \"Flow chamber adhesion assay with receptor-transduced endothelial monolayers plus calcium imaging and chemotaxis controls\",\n      \"pmids\": [\"10227295\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor/signaling pathway mediating the adhesion effect not defined\", \"Did not resolve which endothelial or monocyte molecules execute firm adhesion\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved the chemotactic signaling cascade by placing PKCβ downstream of the CCR2-triggered calcium response, separating the receptor-proximal calcium signal from the effector step needed for migration.\",\n      \"evidence\": \"Isoform-specific antisense knockdown plus PKC inhibitors and calcium measurement in human monocytes\",\n      \"pmids\": [\"12724308\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrates of PKCβ in monocyte migration not identified\", \"Link between calcium signal and PKCβ activation not mapped\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated CCL2 cytoprotection in CNS cells by lowering glutamate and NMDAR1 and identified RANTES neuroprotection as acting via MCP-1 induction, showing the chemokine has neuroprotective roles independent of leukocyte recruitment.\",\n      \"evidence\": \"Neuron/astrocyte apoptosis assays, glutamate measurement, NMDAR1 Western blot, anti-MCP-1 neutralization\",\n      \"pmids\": [\"12753088\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor and intracellular pathway for neuroprotection not defined in this study\", \"In vitro mixed culture only\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified opposing Smad control of CCL2 transcription: Smad-3 cooperates with HIV-1 Tat to stimulate the promoter while Smad-4 represses, mapping direct Smad-Tat interactions, advancing understanding of TGF-β/viral transcriptional input.\",\n      \"evidence\": \"MCP-1 promoter-luciferase reporters and Smad-Tat protein interaction/domain mapping in astrocytic cells\",\n      \"pmids\": [\"12758167\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous promoter occupancy not shown\", \"Context-dependence relative to Smad3 repression in macrophages unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined an estrogen-dependent repression mechanism in which ERβ sequesters Sp1/AP-1 transcriptional activity at the CCL2 promoter without displacing their DNA binding, explaining hormonal suppression of the chemokine.\",\n      \"evidence\": \"Promoter-luciferase reporters, ERβ domain mutants, and co-IP of ERβ with Sp1/AP-1 in keratinocytes\",\n      \"pmids\": [\"12787135\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of ERβ-CCL2 axis not tested\", \"Quantitative contribution of Sp1 vs AP-1 not separated\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Pinpointed Smad3 as the obligate mediator of TGF-β1 repression of CCL2 in macrophages through antagonism of AP-1 DNA binding, with in vivo arteriopathy consequences, defining a key negative transcriptional brake.\",\n      \"evidence\": \"Smad3 gain-of-function, Smad3-KO macrophages, AP-1 binding assay, and cardiac allograft model\",\n      \"pmids\": [\"14752027\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of Smad3-AP-1 antagonism (sequestration vs competition) not fully resolved\", \"Promoter elements bound not mapped\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed cytoprotective and chemotactic CCL2 functions use distinct receptor-coupled pathways, with ERK1/2 (not Gαi) mediating anti-apoptotic protection of cardiomyocytes, formally bifurcating CCL2 signaling outputs.\",\n      \"evidence\": \"Cardiomyocyte hypoxia apoptosis assays with ERK and Gαi (pertussis toxin) inhibitors and Bcl-2 family Western blots\",\n      \"pmids\": [\"16102724\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor coupling ERK in cardiomyocytes not identified\", \"In vitro hypoxia model only\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mapped a PKC→NF-κB pathway driving high-glucose/hyperosmolarity induction of CCL2 in mesothelial cells, distinguishing it from MAPK routes and showing glucocorticoid suppression via IκBα.\",\n      \"evidence\": \"Systematic pharmacological pathway dissection, NF-κB EMSA, and MCP-1 RT-PCR/ELISA in rat mesothelial cells\",\n      \"pmids\": [\"16518329\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter occupancy by NF-κB not shown\", \"Single-cell-type in vitro context\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended the inducer repertoire by showing lipoxygenase product 12(S)-HETE and the myelin-deficient Schwann cell state drive CCL2 through PKC/p38/NADPH oxidase and MEK-ERK respectively, linking lipid and neural-injury signals to chemokine output.\",\n      \"evidence\": \"12/15-LO KO/transgenic mice and macrophage lines; MEK inhibitor CI-1040 in Schwann cells and P0+/- nerves\",\n      \"pmids\": [\"18296557\", \"18383340\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factor endpoints downstream of these kinases not identified\", \"Whether pathways converge on shared promoter elements unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Established CCL2 as an apical, autocrine driver of RANKL-induced osteoclastogenesis acting upstream of DC-STAMP, NFATc1, and cathepsin K, defining a non-immune developmental role for the chemokine.\",\n      \"evidence\": \"MCP-1-KO osteoclast cultures with recombinant rescue and DC-STAMP-KO epistasis; RT-PCR of differentiation markers\",\n      \"pmids\": [\"19364494\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor on osteoclast precursors not confirmed\", \"Single-lab in vitro epistasis\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Connected adrenergic input to CCL2 neuroprotection, showing β2-AR/cAMP induces astrocytic CCL2 that lowers NMDA-dependent glutamate release and calcium entry to protect neurons across multiple injury paradigms.\",\n      \"evidence\": \"Primary co-cultures, MCP-1 promoter reporter, β2-AR antagonist, anti-MCP-1 neutralization, calcium/LDH/OGD readouts\",\n      \"pmids\": [\"19129402\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Neuronal receptor transducing the protective signal not identified\", \"In vivo neuroprotection not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated CCL2/CCR2 is required for angiopoietin-1-driven mural cell recruitment during angiogenesis, broadening its role to vascular wall assembly.\",\n      \"evidence\": \"Aortic ring model with MCP-1-KO and CCR2-KO mice, anti-MCP-1 blockade, recombinant MCP-1, and p38 inhibitor\",\n      \"pmids\": [\"20571857\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mural cell receptor/signaling response not fully defined\", \"Relationship to monocyte recruitment in the same model not separated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified p53 as a direct transcriptional activator binding a defined upstream site required for TNF-α-induced CCL2, with HPV E6-mediated p53 loss abolishing induction, adding tumor-suppressor control of the chemokine.\",\n      \"evidence\": \"EMSA and ChIP for p53 binding, siRNA knockdown, and multiple genetic keratinocyte/Li-Fraumeni systems\",\n      \"pmids\": [\"20406462\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors enabling p53 at the CCL2 promoter not defined\", \"Generality beyond keratinocytes not established\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined IκBζ as a direct positive regulator recruited to the proximal Ccl2 promoter that deposits activating H3K4me3 and is needed for LPS/peptidoglycan-induced secretion and monocyte infiltration in vivo.\",\n      \"evidence\": \"IκBζ-KO macrophages, ChIP for occupancy and H3K4me3, and in vivo peritonitis\",\n      \"pmids\": [\"23547114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How IκBζ cooperates with NF-κB at the promoter not detailed\", \"Histone methyltransferase recruited not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Mapped the lipoprotein-binding determinants of CCL2 to Arg-18/Lys-19 and showed the OxLDL/Lp(a)-bound chemokine retains monocyte-recruiting activity, mechanistically linking CCL2 to oxidized lipid carriers in plasma.\",\n      \"evidence\": \"Site-directed mutagenesis, OxLDL binding assays, E06 anti-OxPL blockade, plasma Lp(a) capture, and migration assays\",\n      \"pmids\": [\"23667177\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological consequence of lipoprotein-bound delivery in vivo not established\", \"Effect on CCR2 affinity not quantified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Added ATF3 as a direct repressor binding ATF/CRE sites in the MCP-1 promoter and revealed exosomal ATF3 RNA as a trans-acting brake limiting macrophage recruitment after renal ischemia/reperfusion.\",\n      \"evidence\": \"ATF3-KO mice, I/R model, promoter binding assay, exosome transfer, and macrophage migration assay\",\n      \"pmids\": [\"24420912\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding evidence relies on single-lab assays\", \"Mechanism of exosomal ATF3 RNA action not detailed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placed CCL2 induction at the apex of the RANKL osteoclastogenesis transcriptional cascade, with >1000-fold early induction preceding CALM1/JUN/NFATc2, refining pathway ordering established by earlier KO work.\",\n      \"evidence\": \"Human CFU-GM osteoclast differentiation with dominant-negative 7ND and temporal qPCR profiling\",\n      \"pmids\": [\"23996571\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor/signal driving the early transcriptional targets not defined\", \"Single-lab temporal profiling\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Extended CCL2/CCR2 signaling to neuroinflammatory pain via a PI3K/Akt-dependent spinal microglial activation mechanism with behavioral readout.\",\n      \"evidence\": \"Bone cancer pain rat model, microglia stimulation, PI3K inhibitor LY294002, intrathecal anti-MCP-1, and allodynia testing\",\n      \"pmids\": [\"25555372\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor identity on microglia not confirmed by genetics\", \"Single-lab model\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Implicated MCP-1/CCR2 in ovarian cancer cell invasion and adhesion, suggesting tumor-cell-intrinsic chemokine signaling, though support rests on antagonist pharmacology alone.\",\n      \"evidence\": \"Transwell invasion/adhesion assays with CCR2 antagonist and CCR2 immunohistochemistry in SKOV-3 cells\",\n      \"pmids\": [\"24222114\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Receptor antagonist only; no genetic confirmation\", \"Single in vitro cell line\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined a CCL2/CCR2→MEK/ERK axis driving triple-negative breast cancer invasion and EMT marker expression, linking autocrine chemokine signaling to tumor cell motility.\",\n      \"evidence\": \"Invasion assays with CCR2 antagonist, MEK inhibitor U0126, MCP-1 siRNA, and EMT marker Western blots\",\n      \"pmids\": [\"29594759\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo metastatic relevance not tested\", \"Single-lab cell-line study\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established a pathogenic CCL2/CCR2 role in ethanol-induced developmental neuroapoptosis acting via TLR4 and GSK3β, using dual genetic and pharmacological tools.\",\n      \"evidence\": \"MCP-1-KO and CCR2-KO mice, neonatal ethanol model, Bindarit/RS504393 inhibitors, co-culture, and signaling analysis\",\n      \"pmids\": [\"29976212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type source vs target of CCL2 not fully separated\", \"Direct link from CCR2 to TLR4 activation not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Resolved an intracellular consequence of CCL2/CCR2 in cardiomyocyte I/R injury, placing CaSR upstream of MCPIP1 to activate ER stress (not autophagy) and drive apoptosis.\",\n      \"evidence\": \"HL-1/primary cardiomyocyte simulated I/R with CCR2 and CaSR inhibitors/activators and ER stress Western blots\",\n      \"pmids\": [\"31774703\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How CCR2 signaling engages CaSR not defined\", \"In vitro only\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified an adiponectin/APPL2-mTORC1 pathway that suppresses TNF-α-induced hepatocyte CCL2, defining a metabolic brake on chemokine-driven liver inflammation.\",\n      \"evidence\": \"Hepatocyte-specific APPL2-KO and adiponectin-KO double-KO epistasis on high-fat diet with mTORC1 analysis\",\n      \"pmids\": [\"34162682\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factor endpoint downstream of mTORC1 at the Ccl2 promoter not identified\", \"Mechanism of mTORC1-CCL2 link not detailed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated hepatocyte-intrinsic Notch/RBPJ transactivation of the Ccl2 promoter as a driver of monocyte-derived macrophage recruitment and fibrosis in NASH, with cell-specific genetic and pharmacological proof.\",\n      \"evidence\": \"Hepatocyte-specific Ccl2-KO and Notch gain-of-function mice, CCR2 inhibitor, RBPJ promoter site analysis, and NASH fibrosis histology\",\n      \"pmids\": [\"36752206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interaction of Notch/RBPJ with other CCL2 regulators not mapped\", \"Human relevance shown only at promoter conservation level\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CCL2's distinct functional outputs—adhesion, chemotaxis, parenchymal cytoprotection, osteoclast/mural cell programs—are selected at the level of receptor coupling and effector choice remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural basis for biased CCR2 signaling defined\", \"Whether non-CCR2 receptors mediate adhesion and cytoprotection not established\", \"In vivo significance of lipoprotein-bound CCL2 delivery not quantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 2, 9, 18]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [11, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 11, 18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 4, 15]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 11, 21, 22, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CCR2\", \"OxLDL\", \"Lp(a)\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}